Nanion Corporate Blog

 

28.09.2018: New NCX assays using iCell cardiomyocytes² in combination with the SURFE²R Technology

We were able to record specific NCX currents with remarkable amplitude in iCell Cardiomyocytes² on the SURFE²R which proofs in a nice and very direct way that NCX is functionally expressed in these cells. By investigating the cells with the CardioExcyte 96 we could show an influence of NCX inhibition on the beating rate. This demonstrates the relevance of cardiac NCX as a potential pharmacological and safety target.

Attend the workshop of FUJIFILM Cellular Dynamics at SPS 2018 and see T. K. Feasters (FCDI) presentation on predictive power of human iPSC-derived cells for in vitro toxicity testing where he will present detailed data on functional evidence of NCX in iCell CM² during CDI´s sponsored session:
Tuesday, October 2 | 12:30 – 1:30 pm | Hoover Room, “Implementing Human iPSC-Derived Cells in Early Safety Assessment and Disease Modeling”
Sonja Stölzle-Feix will present on CiPA mycoyte validation study results of iCell CM²

George O. Okeyo will present a poster (# 0042) on functional assays for cardiac transporters including NCX.

For detailed information on our SPS activities click here.

 

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok